Accessibility Skip to Global Navigation Skip to Local Navigation Skip to Content Skip to Search Skip to Site Map Menu

Biochemistry Seminar | Dr Jillian F. Evans, PharmAria Therapeutics, San Diego

Development of montelukast, a leukotriene antagonist therapy for asthma and allergies

Dr Evans, a proud NZ ex-Pat living in the US will discuss the discovery and biochemistry of leukotrienes and the development of the cysteinyl leukotriene receptor antagonist SingulairTM (montelukast).

She will outline the drug discovery process from understanding leukotriene effects on asthma and allergies, identifying and cloning targets within the leukotriene pathway and the long process to develop an effective, safe therapy that is not a me-too drug.

Dr Evans’s team cloned the CysLT1 receptor after Singulair was launched. The receptor was identified on human lung smooth muscle and inflammatory cells. Montelukast came off patent in 2012 and the generic form was approved by Pharmac in 2018 for New Zealanders suffering from asthma and allergies.

Date Tuesday, 12 March 2019
Time 12:00pm - 1:00pm
Audience All University
Event Category Health Sciences
Event Type Departmental Seminar
LocationBiochemistry Seminar Room 231

Save this event